A Single-Dose, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3090106 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2015
Price : $35 *
At a glance
- Drugs Tibulizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
- 21 Jan 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.